Based on the interim results from the CHRYSALIS phase I trial, in May 2021 the FDA granted accelerated approval for amivantamab as a treatment for NSCLC patients with EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy [45,63]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.